Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Other Operating Expenses (2016 - 2025)

Ligand Pharmaceuticals' Other Operating Expenses history spans 15 years, with the latest figure at $17.3 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 22.9% year-over-year to $17.3 million; the TTM value through Dec 2025 reached $53.5 million, down 24.86%, while the annual FY2023 figure was $2.1 million, N/A changed from the prior year.
  • Other Operating Expenses for Q4 2025 was $17.3 million at Ligand Pharmaceuticals, up from $11.1 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $37.7 million in Q2 2024 and bottomed at $2.1 million in Q3 2023.
  • The 5-year median for Other Operating Expenses is $12.3 million (2023), against an average of $13.5 million.
  • The largest annual shift saw Other Operating Expenses surged 268.87% in 2024 before it crashed 66.96% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $3.8 million in 2021, then soared by 249.45% to $13.3 million in 2022, then crashed by 84.03% to $2.1 million in 2023, then surged by 957.0% to $22.4 million in 2024, then dropped by 22.9% to $17.3 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Other Operating Expenses are $17.3 million (Q4 2025), $11.1 million (Q3 2025), and $12.4 million (Q2 2025).